Your browser doesn't support javascript.
loading
Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.
Skowronski, Danuta M; Chuang, Erica Sy; Sabaiduc, Suzana; Kaweski, Samantha E; Kim, Shinhye; Dickinson, James A; Olsha, Romy; Gubbay, Jonathan B; Zelyas, Nathan; Charest, Hugues; Bastien, Nathalie; Jassem, Agatha N; De Serres, Gaston.
Afiliação
  • Skowronski DM; University of British Columbia, Vancouver, Canada.
  • Chuang ES; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Sabaiduc S; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Kaweski SE; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Kim S; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Dickinson JA; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Olsha R; University of Calgary, Calgary, Canada.
  • Gubbay JB; Public Health Ontario, Toronto, Canada.
  • Zelyas N; University of Toronto, Toronto, Canada.
  • Charest H; Public Health Ontario, Toronto, Canada.
  • Bastien N; Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada.
  • Jassem AN; Institut National de Santé Publique du Québec, Québec, Canada.
  • De Serres G; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Euro Surveill ; 28(5)2023 02.
Article em En | MEDLINE | ID: mdl-36729117
ABSTRACT
The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Euro Surveill Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Euro Surveill Ano de publicação: 2023 Tipo de documento: Article